Evaluation of Efficacy and Safety of Epalrestat (150 mg) Compared to Epalrestat (50 mg) in Patients Suffering from Diabetic Peripheral Neuropathy

Shende, SD; Baig, MS; Doifode, SM

Shende, SD (reprint author), Alkern Labs Ltd, Dept Med Affair, Bombay, Maharashtra, India.

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018; 12 (4): OC15